ABG Sundal Collier acted as a joint bookrunner in connection with the NOK 505m private placement in Nykode Therapeutics ASA

On Tuesday, 24 October 2023, Nykode Therapeutics ASA (“Nykode” or “the Company”) announced the successful completion of a private placement. The transaction comprised 29,549,400 new shares, at a subscription price of NOK 17.1 per share, equalling a total transaction size of NOK 505 million.
The Company intends to use the net proceeds from the private placement to: (i) Advance clinical studies of VB10.16, including in adjuvant setting (post-surgery, recurrence prevention), (ii) Continue pipeline expansion through internal and partnered programs, (iii) Accelerate research activities to further improve Nykode’s technology platform and expand therapeutic scope including into autoimmune indications, and (iv) progress CMC activities. The balance will be used for other general corporate purposes, including general and administrative expenses and working capital.
The private placement was multiple times oversubscribed and saw significant international investor participation.